Humacyte Past Earnings Performance

Past criteria checks 0/6

Humacyte's earnings have been declining at an average annual rate of -19.9%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 69.4% per year.

Key information

-19.9%

Earnings growth rate

71.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-69.4%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Dec 23

Humacyte: FDA Waiting Game Bleeding Company Dry

Dec 14

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Sep 24

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Aug 16
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Jul 17

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05
Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Revenue & Expenses Breakdown

How Humacyte makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:HUMA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1532411
30 Jun 240-140237
31 Mar 240-106200
31 Dec 230-111200
30 Sep 230-892055
30 Jun 230-892037
31 Mar 231-29220
31 Dec 222-12230
30 Sep 22234230
30 Jun 22228220
31 Mar 221-26220
31 Dec 211-26210
30 Sep 211-85180
30 Jun 212-71160
31 Mar 211-69140
31 Dec 201-67120
31 Dec 196-85160

Quality Earnings: HUMA is currently unprofitable.

Growing Profit Margin: HUMA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HUMA is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.

Accelerating Growth: Unable to compare HUMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HUMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: HUMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 03:55
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Humacyte, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Michael GormanBTIG
Kristen KluskaCantor Fitzgerald & Co.